# Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

> **NCT00555594** · PHASE2,PHASE3 · COMPLETED · sponsor: **Asociación para Evitar la Ceguera en México** · enrollment: 18 (actual)

## Conditions studied

- Corneal Neovascularization

## Interventions

- **DRUG:** Bevacizumab (Avastin)

## Key facts

- **NCT ID:** NCT00555594
- **Lead sponsor:** Asociación para Evitar la Ceguera en México
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2006-09
- **Final completion:** 2007-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-08-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00555594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00555594, "Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00555594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*